Ryzodeg is a combination of insulin degludec and insulin aspart in the ratio of 70% and 30%, respectively.
It is the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes1-3.
Compared to biphasic insulin aspart 30, Ryzodeg provides adults with type 2 diabetes successful reductions in HbA1c1, with lower risk of hypoglycaemia.
The company said that as a combination product, Ryzodeg requires fewer daily injections than administering basal and mealtime insulin in separate injections.
Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said Ryzodeg is a new approach to diabetes management, and the company is happy to make it available now for people with diabetes.
"Ryzodeg has documented excellent glucose control and a low risk of hypoglycaemia in clinical trials, and it represents an excellent opportunity for intensification of insulin treatment with fewer injections than other treatment options," Thomsen said.
The company intends to launch Ryzodeg in additional countries across the world within the next year.